Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for medical industry professionals · Sunday, July 15, 2018 · 455,523,967 Articles · 3+ Million Readers

OncBioMune’s Phase 2 Clinical Trial of ProscaVax for Early-Stage Prostate Cancer is Now Included on ClinicalTrials.gov

/EIN News/ -- BATON ROUGE, La., July 09, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, is pleased to report ClinicalTrials.gov has updated its website to now include OncBioMune’s Phase 2 clinical trial evaluating ProscaVax as the first ever therapeutic vaccine for prostate cancer patients in the active surveillance group.  The trial is being hosted at Beth Israel Deaconess Medical Center, a teaching hospital of Harvard University Medical School in Boston, MA, and includes the Dana-Farber Cancer Institute.

ProscaVax is OncBioMune’s lead immunotherapy platform candidate consisting of a combination of prostate cancer associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

The study will evaluate the safety and efficacy of ProscaVax in patients with localized prostate cancer. The goal of the study is to determine if ProscaVax administration results in a change in the rate of prostate cancer progression when compared to a no-treatment control group of active surveillance patients.  Active surveillance is a disease management option for patients with localized prostate cancer that elect to work with their doctor to monitor the disease for progression before taking more drastic intervention measures, such as surgery or radiotherapy.

Details on the trials can be viewed at: https://clinicaltrials.gov/ct2/show/NCT03579654.

“The initiation of this study represents a milestone moment for our company, shareholders and the more than 160,000 men that will learn they have prostate cancer this year,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune.  “For the first time ever, prostate cancer patients in the trial will have a therapeutic vaccine as an option rather than waiting for disease progression or jumping into more invasive treatments options that frequently are accompanied by very unpleasant side effects, such as urinary incontinence and impotence.  We look forward to the commencement of enrollment and to the future where we will learn more about the efficacy of ProscaVax as a front-line treatment for prostate cancer.”

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About Prostate Cancer

According to the American Cancer Society (ACS), prostate cancer is the most common type of cancer in men other than skin cancer, with about 1 in 9 men diagnosed during their lifetime.  ACS estimates that about 164,690 new cases of prostate cancer will be diagnosed during 2018 and approximately 29,430 men will die from the disease this year.  Prostate cancer is the second leading cause of cancer death in men, trailing only lung cancer.  Approximately 2.9 million men are living with prostate cancer today.  The average age of diagnosis is 66, with the disease considered rare in men under the age of 40.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, based on their proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. Our lead pipeline product, ProscaVax™, has successfully completed enrollment and vaccination of the prostate cancer patients and is collecting long-term follow-up results for the 1a portion of their Phase 1a/1b clinical trial.  Due to the impressive results and proven safety profile of ProscaVax™, OncBioMune is forgoing the 1b portion of the trial to advance ProscaVax™ into Phase 2 clinical trials. A Phase 2 clinical trial is scheduled to commence at Beth Israel Deaconess Medical Center, a Harvard University teaching hospital evaluating ProscaVax as a front-line therapy in prostate cancer patients in the “active surveillance” category, representing the first mid-stage trial of an immunotherapeutic vaccine in this patient population.  OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Contact:

OncBioMune Pharmaceuticals, Inc.
Jonathan F. Head, PhD
Chief Executive Officer and Chairman of the Board
Jhead@oncbiomune.com

Powered by EIN News
Distribution channels: Technology
Submit your press release